Chinese Regulators Fast-Track Promising Two-Drug Combination for Blood Cancer Treatment
Beijing, Tuesday, 4 August 2026.
China fast-tracked InnoCare’s dual-drug therapy for blood cancer after clinical trials demonstrated a 100% response rate, significantly accelerating the approval process for this innovative treatment.
Regulatory Milestone Achieved in China
InnoCare Pharma (HKEX: 09969; SSE: 688428) announced that the China National Medical Products Administration (NMPA) Center for Drug Evaluation (CDE) granted Breakthrough Therapy Designation (BTD) to the combination of orelabrutinib and mesutoclax [1]. This designation applies to the treatment of patients with marginal zone lymphoma (MZL) who have received at least one prior therapy [1]. The announcement was made on 3 August 2026, marking a significant regulatory milestone for the company’s oncology portfolio [1].
Clinical Efficacy and Drug Mechanism
Data presented at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting showed the orelabrutinib/mesutoclax combination achieved a 100% overall response rate (ORR) in MZL patients with at least one prior therapy [1]. Orelabrutinib is a novel Bruton’s tyrosine kinase (BTK) inhibitor developed by InnoCare, while mesutoclax functions by selectively inhibiting BCL2 to restore apoptosis in cancer cells [1]. Mesutoclax previously received BTD recognition in China for treating mantle cell lymphoma (MCL) in patients previously treated with a BTK inhibitor [1].
Company Portfolio and Strategic Outlook
Dr. Jasmine Cui, Co-founder, Chairwoman, and CEO of InnoCare, stated that the BTD will help accelerate clinical trials to provide better treatment options for more patients [1]. InnoCare Pharma is a commercial-stage biopharmaceutical company focused on cancer and autoimmune disease treatments [1]. The company’s current portfolio includes three approved drugs: orelabrutinib, tafasitamab, and zurletrectinib [1].